Literature DB >> 6371871

A double-blind, controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.

G Chouinard, L Annable, W Campbell, D Boisvert, J Bradwejn.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6371871

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


× No keyword cloud information.
  7 in total

Review 1.  Depot haloperidol decanoate for schizophrenia.

Authors:  S Quraishi; A David
Journal:  Cochrane Database Syst Rev       Date:  2000

2.  Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants.

Authors:  Giovanni Ostuzzi; Federico Bertolini; Federico Tedeschi; Giovanni Vita; Paolo Brambilla; Lorenzo Del Fabro; Chiara Gastaldon; Davide Papola; Marianna Purgato; Guido Nosari; Cinzia Del Giovane; Christoph U Correll; Corrado Barbui
Journal:  World Psychiatry       Date:  2022-06       Impact factor: 49.548

3.  Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.

Authors:  D H Wiles; R G McCreadie; A Whitehead
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 4.  Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis.

Authors:  R Beresford; A Ward
Journal:  Drugs       Date:  1987-01       Impact factor: 9.546

Review 5.  Long-term depot antipsychotics. A risk-benefit assessment.

Authors:  T R Barnes; D A Curson
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

6.  Characteristics of oral movements in rats during and after chronic haloperidol and fluphenazine administration.

Authors:  R E See; E D Levin; G D Ellison
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 7.  Depot antipsychotic drugs. Place in therapy.

Authors:  J M Davis; L Matalon; M D Watanabe; L Blake; L ] Metalon L [corrected to Matalon
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.